Aura Biosciences, Inc. AURA | NASDAQ
|2026-09-09
Company Overview:
5 Year AURA Performance Metrics:
Build Custom Charts
AURA Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for AURA
Based on past 5-year performance, here are AURA growth metrics:
Share price CAGR of -16.13%
Dividend CAGR of +0%
Using AURA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| AURA (DRIP) | AURA - No DRIP | |
|---|---|---|
| Current Price | $6.14 | $6.14 |
| Start Shares | 1,628.66 | 1,628.66 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,628.66 | 1,628.66 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $1.06 | $6.14 |
| Total Dividends | $0 | $0 |
| Final Value | $1,721 | $10,000 |
NOTE: Above numbers are our estimate based on AURA's Dividend and Price CAGR over past 5 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Aura Biosciences, Inc. (AURA) had its IPO on , and is traded on NASDAQ stock exchange.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.
AURA website: https://www.aurabiosciences.com
DCF Model — AURA
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
